Terms ending in 2033
Supernus Pharmaceuticals, Inc.
Every in-force patent on Supernus Pharmaceuticals, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,358,204 | Formulations of Viloxazine In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,603,853 | Formulations of Viloxazine In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 10,265,319 | Formulations of Viloxazine In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 8,957,206 | Methods of Producing Molindone and Its Salts In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,802,893 | Methods of Producing Molindone and Its Salts In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 10,081,595 | Methods of Producing Molindone and Its Salts In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 10,676,432 | Methods of Producing Molindone and Its Salts In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,117,862 | Methods of Producing Molindone and Its Salts In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,562,011 | Methods of Producing Molindone and Its Salts In force · High confidence | Supernus Pharmaceuticals, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.